Evotec and Boehringer Ingelheim join forces on GPCR research
Evotec OAI and Evotec Neurosciences have entered into a three-year research collaboration with Boehringer Ingelheim to jointly identify and develop small molecule therapeutics acting on selected G-Protein Coupled Receptors (GPCRs).
Evotec OAI and Evotec Neurosciences have entered into a three-year research collaboration with Boehringer Ingelheim to jointly identify and develop small molecule therapeutics acting on selected G-Protein Coupled Receptors (GPCRs).
The initial focus will be on CNS diseases. Boehringer Ingelheim will have global responsibility for all clinical development activities, manufacture and commercialisation of the compounds identified in the collaboration.
Under the terms of the agreement, Boehringer Ingelheim, Evotec Neurosciences and Evotec OAI will jointly identify and develop pre-clinical development candidates. In return for Evotec Neurosciences' and Evotec OAI's contributions to the research programme, Boehringer Ingelheim will make research payments, additional discovery and development payments, and royalties.
'The broad GPCR-based strategic alliance of Boe-hringer Ingelheim with Evotec OAI and Evotec Neuro-sciences should establish a powerful platform for the discovery of promising new medicines in the field of Central Nervous System diseases and other therapeutic areas,' said Professor Dieter Hinzen, head of r&d at Boehringer Ingelheim Germany. 'We are delighted to work together with Evotec OAI and Evotec Neurosciences in a joint competent scientific team.'